In light of these findings, we searched our in-house genomic sequencing platform and identified seven additional patients with MYC amplified HNSCC along with 48 MYC wild-type matched controls, to further elucidate the broader clinicopathologic characteristics of MYC-driven disease. The gene discussed is MYC; the disease is head and neck squamous cell carcinoma.